Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide

被引:7
|
作者
Wang, Fulin [1 ]
Qiao, Guangyu [2 ]
Lou, Xin [3 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China
关键词
Anaplastic oligodendroglioma; Spinal cord tumor; 1p deletion; Temozolomide; PHASE-II; GLIOMAS; CHEMOTHERAPY; TUMORS; CHILD;
D O I
10.1007/s11060-010-0493-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary spinal cord oligodendroglial tumor is very rare, and in only one patient with spinal cord oligodendroglioma has a deletion of chromosome 1p/19q been reported. We present the case of an 18-year-old girl, who had one-year lower back pain and one-month lower limb weakness. Magnetic resonance images of the spinal cord showed an intramedullary mass from level T8 to T10, which was then radically removed. Histology revealed an anaplastic oligodendroglioma. The patient was treated with radiotherapy postoperatively. Eight months after the treatment, follow-up magnetic resonance images disclosed an enhancing intramedullary mass at level T4-T8; recurrence of the tumor was therefore diagnosed. Maximum surgical removal of the recurrent tumor was performed, diagnosis of anaplastic oligodendroglioma was made, and a chromosome 1p deletion was determined by FISH. After treatment with temozolomide for six months, the patient had a remarkable improvement of her lower limb symptoms, and complete imaging regression of the residual tumor showed no evidence of recurrence at any other sites. The most recent MRI of brain and spinal cord showed postoperative changes without evidence of tumor recurrence of the spine and oligodendrogliomatosis along the cerebral-spinal axis. To our knowledge, this is the first report of a recurrent anaplastic oligodendroglioma with 1p deletion occurring in the spinal cord. It is also the first case of the patient with recurrent intramedullary anaplastic oligodendroglioma who had a significant clinical improvement and complete imaging remission after subtotal resection then treatment with temozolomide chemotherapy.
引用
收藏
页码:387 / 394
页数:8
相关论文
共 50 条
  • [41] ANAPLASTIC EPENDYMOMA OF THE SPINAL-CORD IN CHILDHOOD - A CASE-REPORT
    FUJIYAMA, K
    KISHIKAWA, M
    FUJII, H
    MORIYAMA, T
    FUCHIGAMI, K
    ISEKI, M
    SHINKAI, K
    ACTA PATHOLOGICA JAPONICA, 1990, 40 (05): : 376 - 382
  • [42] Extracranial Metastasis of Anaplastic Oligodendroglioma With 1p19q Loss of Heterozygosity -Case Report-
    Noshita, Nobuo
    Mashiyama, Shoji
    Fukawa, Osamu
    Asano, Shigeyuki
    Watanabe, Mika
    Tominaga, Teiji
    NEUROLOGIA MEDICO-CHIRURGICA, 2010, 50 (02) : 161 - 164
  • [43] Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review
    Shimizu, Hiroyuki
    Motomura, Kazuya
    Ohka, Fumiharu
    Aoki, Kosuke
    Tanahashi, Kuniaki
    Hirano, Masaki
    Chalise, Lushun
    Nishikawa, Tomohide
    Yamaguchi, Junya
    Wakabayashi, Toshihiko
    Natsume, Atsushi
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [44] 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
    Kouwenhoven, Mathilde C. M.
    Kros, Johan M.
    French, Pim J.
    Biemond-ter Stege, Elize M.
    Graveland, Wilfried J.
    Taphoorn, Martin J. B.
    Brandes, Alba A.
    van den Bent, Martin J.
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) : 2499 - 2503
  • [45] Correction: Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report
    Hirokazu Takami
    Akitake Mukasa
    Shunsaku Takayanagi
    Tsukasa Koike
    Reiko Matsuura
    Masako Ikemura
    Tetsuo Ushiku
    Gakushi Yoshikawa
    Junji Shibahara
    Shota Tanaka
    Nobuhito Saito
    Brain Tumor Pathology, 2023, 40 : 142 - 142
  • [46] Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report
    Demeulenaere, Marieke
    Duerinck, Johnny
    Du Four, Stephanie
    Fostier, Karel
    Michotte, Alex
    Neyns, Bart
    ANTICANCER RESEARCH, 2016, 36 (08) : 4145 - 4149
  • [47] Anaplastic oligodendroglioma: Distinctive morphologic and immunophenotypic subsets associated with combined 1p/19q allelic loss
    Seethala, RR
    Ribalta, T
    Aldalpe, KD
    McDonald, JM
    Fuller, GN
    MODERN PATHOLOGY, 2005, 18 : 294A - 295A
  • [48] Anaplastic oligodendroglioma: Distinctive morphologic and immunophenotypic subsets associated with combined 1p/19q allelic loss
    Seethala, RR
    Ribalta, T
    Aldape, KD
    McDonald, JM
    Fuller, GN
    LABORATORY INVESTIGATION, 2005, 85 : 294A - 295A
  • [49] Oligodendroglioma Patients with 1p/19q Co-deletion Treated with Early or Delayed Radiation Therapy over the Last Two Decades: A Multi-institutional Report
    Lin, A. J.
    Kane, L.
    Molitoris, J. K.
    Smith, D.
    Badiyan, S. N.
    Wang, T. J. C.
    Kruser, T. J.
    Huang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E282 - E283
  • [50] Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma
    Zhao, Binghao
    Ma, Wenbin
    LANCET ONCOLOGY, 2021, 22 (08): : E345 - E345